🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Carla Casulo

University of Rochester Medicine

ORCID: 0000-0003-4998-9932

Also affiliated with University of Rochester

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.1Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Papers

Driven by 11 papers — median percentile 90. Top paper: “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The Lancet(2020)10.1016/s0140-6736(20)31187-9

N/A

11.9DataRank · unranked

1804 citations

Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera +95 more

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

The Lancet Haematology(2022)10.1016/s2352-3026(22)00033-3

N/A

0.628DataRank · unranked

65 citations

Melissa C. Larson, Julianne J. Lunde, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +19 more

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Hematological Oncology(2023)10.1002/hon.3163_5

N/A

0.464DataRank · unranked

21 citations

Michael LeBlanc, Sharon M. Castellino, Huilin Li, Sarah C. Rutherford, Andrew M. Evens +41 more

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7503

N/A

0.449DataRank · unranked

19 citations

Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang +15 more

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study

American Journal of Hematology(2025)10.1002/ajh.27630

N/A

0.409DataRank · unranked

10 citations

Jean L. Koff, Melissa C. Larson, Brad S. Kahl, Carla Casulo, Izidore S. Lossos +25 more

Current landscape of frontline and relapsed follicular lymphoma trials

Blood Neoplasia(2025)10.1016/j.bneo.2025.100131

N/A

0.208DataRank · unranked

3 citations

Carla Casulo, Lawrence Cheng Kiat Ng

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Blood Advances(2025)10.1182/bloodadvances.2025018079

N/A

0.208DataRank · unranked

3 citations

Sarah C. Rutherford, Stephen M. Ansell, Philippe Armand, John P. Leonard, Loretta J. Nastoupil +20 more

Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.7573

N/A

0.104DataRank · unranked

1 citations

Melissa C. Larson, Jonathan R Day, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +15 more

29 | A COMPARATIVE ANALYSIS OF HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA AT DIAGNOSIS (COMPOSITE LYMPHOMA) AND SEQUENTIALLY TRANSFORMED FOLLICULAR LYMPHOMA

Hematological Oncology(2025)10.1002/hon.70093_29

N/A

0DataRank · unranked

0 citations

Melissa C. Larson, Jonathan Day, Urshila Durani, Mazie Tsang, Dai Chihara +22 more

Defining primary refractory large B-cell lymphoma

Blood Advances(2024)10.1182/bloodadvances.2024012760

N/A

0DataRank · unranked

32 citations

Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J. Maurer, Amy Ayers +15 more